14 / 31
Tumour responses occur earlier, last longer and deeper with panitumumab
Panitumumab
+ mFOLFOX6*
Bevacizumab
+ mFOLFOX6*
HR/OR (95% CI)
P-value
ETS ≥ 30% at Week 8, n (%)
51 (64)
33 (45)
1.99 (0.99‒4.10)
0.052
ETS ≥ 20% at Week 8, n (%)
60 (75)
46 (62)
1.67 (0.78‒3.58)
0.21
Median DoR, months
11.4
9.0
0.59 (0.39‒0.88)
0.011
†
Median TTR, months
2.3
3.8
1.19 (0.81‒1.74)
0.37
†
Median DpR, %
(Q1, Q3)
65.0
(45.7, 89.5)
46.3
(29.5, 63.3)
-
0.0018
‡
PEAK
: ETS, DoR, TTR and DpR (
RASwt
, final analysis)
Rivera F, et al. Eur J Cancer 2015;51(Suppl 3):S1‒S810.